Tag:
Agenus
Latest Headlines
Latest Headlines
Personalized brain cancer vaccine improves survival
Phase II data for Agenus' HSPPC-96 vaccine (also known as vitespen) showed glioblasoma patients living longer, which could offer a glimmer of hope.
Is Agenus on GSK's shopping list?
It's been a busy week or two for GlaxoSmithKline ($GSK)--the company has extended its agreement with Agenus ($AGEN), submitted two vaccines for approval and created a joint venture.
Agenus inks Oncophage cancer vaccine deal with Russian company
Cancer vaccine developer Agenus has inked a licensing, development and manufacturing technology transfer agreement with Russian drug company NewVac. Under the deal, NewVac gets to manufacture, market...
Agenus encouraged by early HerpV results
Lexington, MA-based Agenus reported promising Phase I results of its recombinant therapeutic vaccine HerpV for the treatment of genital herpes in a study published in the journal Vaccine. The
Cancer immunotherapies in vogue as specialists seek a "cure"
Now that Provenge and Yervoy have been approved, specialists are keying in on a new generation of immunotherapies that promise to change the standard of care for cancer. As Stephen Hodi, director of
